1/12 Tweetorial on initial therapy in older adults with #AML at #ASH21. We presented on CPX-351 vs ven/aza. There was no difference in OS. HR 0.88 with 95%CI crossing 1. OS at 2yrs 28% both arms and median OS 13 vs 11 mos tinyurl.com/2p95bn78. #leusm 2/12 We looked at 656 patients at Penn and across the nation with Flatiron. Ven/aza patients were older, more likely to be treated in community rather than academic centers and more had de novo AML.